Interaction Between Determinants Governing Urine Volume in Patients With ADPKD on Tolvaptan and its Impact on Quality of Life

IntroductionAutosomal dominant polycystic kidney disease (ADPKD) is the most prevalent genetic cause of failure. Tolvaptan, a vasopressin 2 receptor antagonist, first drug with proven disease-modifying activity. Long-term treatment adherence crucial, but considerable fraction patients discontinue treatment, because aquaretic side effects.MethodsTwenty-four-hour urine was collected in 75 ADPKD during up-titration tolvaptan and, combination clinical characteristics, examined to identify factors influencing volume. Patient-reported outcomes were analyzed using Short Form-12 (SF-12) and patient-reported questionnaires reporting micturition frequency burden volume.ResultsInitiation therapy led large increase volume followed by only minor further up-dosing. Younger better function experienced larger relative rise. Twenty-four-hour osmolality dropped about 50% after initiation independently dose, proportion achieving adequate suppression. Sodium potassium intake turned out be significant modifiable for multivariate linear regression models, whereas age weight could identified as nonmodifiable factors. No change quality life (QoL) detected relation or SF-12 questionnaires, finding that supported results assessment.ConclusionThis study provides an in-detail analysis associated degree polyuria on puts them into context QoL. These findings will contribute optimized patient counseling regarding this option ADPKD. Autosomal effects. Initiation assessment. This